Search research articles
Contact Us
Filters
Showing results (61-70 of 86) with videos related to
Page
of 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 10, 2017
Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205)
Madhur K Garg, Fengmin Zhao, Joseph A Sparano, et al.
Breast Cancer Research and Treatment
|
June 6, 2019
Neuronatin is a modifier of estrogen receptor-positive breast cancer incidence and outcome
Cody Plasterer, Shirng-Wern Tsaih, Amy R Peck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2022
Phase II Study of Copanlisib in Patients With Tumors With <i>PIK3CA</i> Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F
Senthil Damodaran, Fengmin Zhao, Dustin A Deming, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 12, 2018
Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling
Thai H Tran, Fransiscus E Utama, Takahiro Sato, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 8, 2020
Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i> Mutations: Results of the NCI-MATCH Trial Subprotocol H
April K S Salama, Shuli Li, Erin R Macrae, et al.
JAMA Oncology
|
December 30, 2020
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial
Kevin Kalinsky, Fangxin Hong, Carolyn K McCourt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 12, 2020
Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)
Douglas B Johnson, Fengmin Zhao, Marcus Noel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 19, 2024
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Vered Stearns, Opeyemi A Jegede, Victor T-S Chang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2024
ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer
Bryan P Schneider, Fengmin Zhao, Tarah J Ballinger, et al.
JCO Precision Oncology
|
April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2
Jun Gong, Alain C Mita, Zihan Wei, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 86) with videos related to
Sort By:
Page
of 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 10, 2017
Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205)
Madhur K Garg, Fengmin Zhao, Joseph A Sparano, et al.
Breast Cancer Research and Treatment
|
June 6, 2019
Neuronatin is a modifier of estrogen receptor-positive breast cancer incidence and outcome
Cody Plasterer, Shirng-Wern Tsaih, Amy R Peck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2022
Phase II Study of Copanlisib in Patients With Tumors With <i>PIK3CA</i> Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F
Senthil Damodaran, Fengmin Zhao, Dustin A Deming, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 12, 2018
Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling
Thai H Tran, Fransiscus E Utama, Takahiro Sato, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 8, 2020
Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i> Mutations: Results of the NCI-MATCH Trial Subprotocol H
April K S Salama, Shuli Li, Erin R Macrae, et al.
JAMA Oncology
|
December 30, 2020
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial
Kevin Kalinsky, Fangxin Hong, Carolyn K McCourt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 12, 2020
Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)
Douglas B Johnson, Fengmin Zhao, Marcus Noel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 19, 2024
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Vered Stearns, Opeyemi A Jegede, Victor T-S Chang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2024
ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer
Bryan P Schneider, Fengmin Zhao, Tarah J Ballinger, et al.
JCO Precision Oncology
|
April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2
Jun Gong, Alain C Mita, Zihan Wei, et al.
Page
of 9